Friday, November 14, 2025

DH25024 Nanoparticles as Robots in the Blood V01 141125

 

Magnetic nanoparticles that successfully navigate complex blood vessels may be ready for clinical trials

Microrobots finding their way
The latest ETH micro robot is this small. Credit: Luca Donati / lad.studio Zurich

Every year, 12 million people worldwide suffer a stroke; many die or are permanently impaired. Currently, drugs are administered to dissolve the thrombus that blocks the blood vessel. These drugs spread throughout the entire body, meaning a high dose must be administered to ensure that the necessary amount reaches the thrombus. This can cause serious side effects, such as internal bleeding.

Since medicines are often only needed in specific areas of the body,  has long been searching for a way to use microrobots to deliver pharmaceuticals to where they need to be: in the case of a stroke, directly to the stroke-related thrombus.

Now, a team of researchers at ETH Zurich has made major breakthroughs on several levels. They have published their findings in Science.

Precision nanoparticles required

The  the researchers use comprises a proprietary spherical  made of a soluble gel shell that they can control with magnets and guide through the body to its destination. Iron oxide nanoparticles in the capsule provide the .

"Because the vessels in the  are so small, there is a limit to how big the capsule can be. The  is to ensure that a capsule this small also has sufficient magnetic properties," explains Fabian Landers, lead author of the paper and a postdoctoral researcher at the Multi-Scale Robotics Lab at ETH Zurich.

The microrobot also needs a contrast agent to enable doctors to track via X-ray how it is moving through the vessels. The researchers focused on tantalum nanoparticles, which are commonly used in medicine but are more challenging to control due to their greater density and weight.

"Combining magnetic functionality, imaging visibility and  in a single microrobot required perfect synergy between materials science and robotics engineering, which has taken us many years to successfully achieve," says ETH Professor Bradley Nelson, who has been researching microrobots for decades.

Professor Salvador Pané, a chemist at the Institute of Robotics and Intelligent Systems, and his team developed precision  that enable this delicate balancing act.

Special catheter releases drug-loaded capsule

The microrobots also contain the active ingredient they need to deliver. The researchers successfully loaded the microrobots with common drugs for a variety of applications—in this case, a thrombus-dissolving agent, an antibiotic or tumor medication.

These drugs were released by a high-frequency  that heats the magnetic nanoparticles, dissolving the gel shell and the microrobot.

The researchers used a two-step strategy to bring the microrobot close to its target: first, they injected the microrobot into the blood or cerebrospinal fluid via a catheter. They went on to use an electromagnetic navigation system to guide the magnetic microrobot to the target location.

The catheter's design is based on a commercially available model with an internal guidewire connected to a flexible polymer gripper. When pushed beyond the external guide, the polymer gripper opens and releases the microrobot.

Swimming against the current—navigating blood vessels

To precisely steer the microrobots, the researchers developed a modular electromagnetic navigation system suitable for use in the operating theater.

"The speed of blood flow in the human arterial system varies a lot depending on location. This makes navigating a microrobot very complex," explains Nelson. The researchers combined three different magnetic navigation strategies that allowed them to navigate in all regions of the arteries of the head.

This allows them to roll the capsule along the vessel wall using a rotating magnetic field. The capsule can be guided to its target with enormous precision at a speed of 4 millimeters per second.

Microrobots finding their way
Graphical representation of the various navigation options. Credit: ETH Zurich

In a different model, the capsule is moved using a magnetic field gradient: the magnetic field is stronger in one place than in another. This pulls the microrobot in the vessel towards the stronger field. The capsule can even go against the current—and at a considerable flow velocity of over 20 centimeters per second.

"It's remarkable how much blood flows through our vessels and at such high speed. Our navigation system must be able to withstand all of that," says Landers.

When the microrobot reaches a junction in the vessels that would be difficult to maneuver through, in-flow navigation comes into play. The magnetic gradient is directed against the wall of the vessel in such a way that the capsule is carried along into the correct vessel.

By integrating these three navigation strategies, the researchers gain effective control over the microrobots across various flow conditions and anatomical scenarios. In more than 95% of the cases tested, the capsule successfully delivered the drug to the correct location.

"Magnetic fields and gradients are ideal for minimally invasive procedures because they penetrate deep into the body and—at least at the strengths and frequencies we use—have no detrimental effect on the body," explains Nelson.

Innovation not stopping at robotics

To test the microrobots and their navigation in a realistic environment, the researchers developed silicone models that accurately replicate the vessels of patients and animals. These vessel models are so realistic that they are now being used in medical training and are being marketed by ETH spin-off Swiss Vascular.

"The models are crucial for us, as we practiced extensively to optimize the strategy and its components. You can't do that with animals," explains Pané. In the model, the researchers were able to target and dissolve a blood clot.

After numerous successful trials in the model, the team sought to demonstrate what the microrobot could achieve under real clinical conditions. First, they were able to demonstrate in pigs that all three navigation methods work and that the microrobot remains clearly visible throughout the entire procedure. Second, they navigated microrobots through the cerebral fluid of a sheep.

Landers is particularly pleased. "This complex anatomical environment has enormous potential for further therapeutic interventions, which is why we were so excited that the microrobot was able to find its way in this environment too."

Applications beyond vascular occlusions

In addition to treating thrombosis, these new microrobots could also be used for localized infections or tumors. At every stage of development, the research team has remained focused on their goal: to ensure that everything they create is ready for use in operating theaters as soon as possible. The next goal is to begin human clinical trials as quickly as possible.

Speaking about what motivates the whole team, Landers says, "Doctors are already doing an incredible job in hospitals. What drives us is the knowledge that we have a technology that enables us to help patients faster and more effectively and to give them new hope through innovative therapies."

Monday, November 3, 2025

DH25023 Heart gene repairs heart. V01 041125

 Hearts could learn to heal themselves


Rhys Blakely - Science Editor

For decades cardiologists have had to accept that a damaged heart stays damaged. Once a heart attack kills off muscle cells they are gone for good, replaced by scar tissue that weakens the organ and often leads to heart failure.

That may be about to change, thanks to a team of scientists who have found a way of coaxing the heart to heal itself.

By reawakening a dormant gene known as CCNA2, which produces a protein called cyclin A2, researchers at Mount Sinai Hospital in New York made adult human heart cells divide and multiply in a laboratory — something long thought impossible. The results, published in the Nature Regenerative Medicine journal, suggest it may one day be possible to regrow heart tissue after injury, reducing the need for transplants or implanted pumps.

In Britain, more than 100,000 people are admitted to hospital each year after a heart attack, which equates to roughly one every five minutes.

A heart attack occurs when blood flow to part of the heart is blocked, starving it of oxygen and causing muscle tissue to die. About one million people in the UK live with heart failure, a chronic condition in which the heart becomes too weak to pump blood efficiently, often as a result of damage done by a heart attack.

In the womb, CCNA2 drives the growth of the developing heart — but the gene switches off soon after birth. Hina Chaudhry, the director of cardiovascular regenerative medicine at Mount Sinai’s Icahn School of Medicine, has spent nearly 20 years trying to reverse that process.

In 2014, her team became the first to regenerate a large mammal’s heart by reactivating CCNA2. They used pigs, whose hearts closely resemble those of humans, but now her group has produced evidence suggesting that the same approach could work in adult human heart cells.

After using a harmless virus to deliver an active version of CCNA2 into heart muscle cells taken from donor organs aged 21, 41 and 55, they watched the gene take effect using microscopes.

The most striking results were seen in the two older hearts. After the gene therapy, these mature cells began to stir. Under the microscope, the researchers watched them round up, reorganise, and then split in two.

When heart cells divide in the lab, they can lose their rhythm or shape, which would make them useless, or dangerous. In this study, the new cells retained the structure and proteins that give heart muscle its strength.

The next step will be to seek approval from America’s Food and Drug Administration to test the therapy in people with heart disease. “This is the culmination of nearly two decades of work,” Chaudhry said. “Now we’ve brought that vision one step closer to patients.”

Saturday, November 1, 2025

DH25022 Brilliant Biology Author - Nessa Carey. V01 021125

 Nessa Carey


Here’s a detailed overview of Nessa Carey — her background, career, key ideas, and why she’s a noteworthy figure.


Background & Career

She is a British molecular biologist whose academic training includes a PhD in virology from University of Edinburgh. 

Early in her career she worked at the Metropolitan Police Forensic Science Lab in London for five years, while studying part-time. 

She then entered academia: post-doctoral research in human genetics, then lecturer and senior lecturer in molecular biology at Imperial College London. 

Later she moved into industry: working in biotech and pharmaceutical sectors (including external R&D/innovation roles). 

She now combines roles: visiting professor at Imperial College, consultant/trainer in translating research into societal/industrial benefits, and author. 


Areas of Expertise & Themes

Epigenetics: One of her major areas. She writes and speaks about how beyond the DNA sequence, the regulation and modification of genes (epigenetic mechanisms) are crucial for understanding biology, disease, inheritance. 

“Junk DNA” / Non-coding genome: Exploring the parts of the genome that don’t code for proteins but nonetheless have important roles. Her book on this topic gives a popular science take. 

Technology transfer / Translational research: Given her industry experience, she emphasizes moving from basic science to applications (therapies, diagnostics, commercialization). 


Selected Publications / Popular Science Books

The Epigenetics Revolution: How Modern Biology Is Rewriting Our Understanding of Genetics, Disease, and Inheritance (2011) — Introduces epigenetics to a general audience. 

Junk DNA: A Journey Through the Dark Matter of the Genome (2015) — Deals with what was once called “junk” DNA and its unexpected roles. 

Hacking the Code of Life: How Gene Editing Will Rewrite Our Futures (2019) — On gene-editing technologies (like CRISPR), their potentials and ethical/societal implications. 


Why She Matters & What She Brings

She bridges academic science and industry: This dual background gives her a perspective on how scientific discoveries can move from “bench to bedside” (or product).

She is a communicator of science: Her books aim to make complex biological topics accessible to non specialists. For example, reviewers describe The Epigenetics Revolution as “a mercifully clear writer… using everyday metaphors”. 

She tackles big questions: How identical DNA can lead to different outcomes, how environment/experience can shape gene expression, how new technologies (gene editing) might change life/health. These are relevant both scientifically and socially.

She is involved in translational/entrepreneurial science education: For example, she was an Entrepreneur-in-Residence at the University of Oxford Medical Sciences Division, helping to build an innovation ecosystem. 


Key Take-Away Concepts

DNA is not the whole story: It’s the starting script, but how that script is read/modified (“epigenetics”) matters hugely.

“Junk DNA” is a misnomer: Large parts of the genome previously thought inert have biological functions, regulatory roles, are relevant to disease.

The interface of science and society: Advances in biology (gene editing, epigenetics) raise questions about ethics, regulation, health, inequity.

Career paths in science are diverse: Her own trajectory shows that one can move between academia, industry, public engagement, policy/translation.


Personal / Miscellaneous Details

She grew up attending state schools, which she mentions in public engagement contexts, emphasising accessibility of science. 

Outside work she has interests such as bird-watching, small-holding/gardening. 


Research Papers


Here are a few peer-reviewed research papers and academic articles by or associated with Nessa Carey, along with brief summaries and links (where available). Please note that a full exhaustive list of her ~30 peer-reviewed papers is not easily accessible in one place.


Selected Papers

1. Carey, N. “Epigenetics for the masses: more than Audrey Hepburn and yellow mice?” International Journal of Epidemiology, Vol. 41, Issue 1, February 2012.

This is a commentary/review piece reflecting on her book The Epigenetics Revolution and the broader epigenetics field. 

It explores how the “popular science” of epigenetics connects to epidemiology and public health.

2. (While not a typical original research article, this relates to her PhD thesis) “Studies on the extracellular envelope glycoprotein of maedi-visna virus.” (PhD thesis) 

Her doctoral work (at University of Edinburgh) focused on virology (maedi-visna virus).

Provides a foundation for her molecular biology credentials.

3. (More broadly) Carey has indicated that she has “published over 30 peer-reviewed papers on epigenetics and other aspects of biology.” 

Unfortunately, I was not able to locate a publicly accessible, complete list of all her original research articles with full bibliographic details.


Notes & Tips for Further Search

Because many of her publications are likely in academic journals behind paywalls, you may need institutional access (university library) to view full texts.

Searching academic databases (e.g., PubMed, Web of Science) for “Nessa Carey” + keywords like epigenetics, DNA methylation, gene expression may uncover more original research papers.

Her website lists her books and popular science material, but does not provide a full detailed research-paper bibliography. 


Great — here are 8 peer-reviewed papers (research articles and invited reviews) that Nessa Carey authored or co-authored, with full citations, a one-line summary for each, and direct links to the PubMed/PMC records so you can open the full text or export citations.


1. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs S, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008 Jan 15;409(2):581–589. doi:10.1042/BJ20070779.

Short summary: biochemical characterization of HDAC inhibitor selectivity across isoforms — useful background for epigenetic drug work. 

2. La Thangue NB, Carey N. Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol. 2006 Aug;6(4):369–375. doi:10.1016/j.coph.2006.03.010.

Short summary: an early review on the therapeutic potential and development of HDAC inhibitors. 

3. Scoumanne A, Kalamati T, Moss J, Powell JT, Gosling M, Carey N. Generation and characterisation of human saphenous vein smooth muscle cell lines. (Comparative study) Eur J Vasc Endovasc Surg. 2002. doi:10.1016/S0021-9150(01)00538-X.

Short summary: methodology / characterisation paper from her Imperial College vascular biology work. 

4. Sultan S, Gosling M, Abu-Hayyeh S, Carey N, Powell JT. Flow-dependent increase of ICAM-1 on saphenous vein endothelium is sensitive to apamin. Am J Physiol Heart Circ Physiol. 2004; (PMID:14962835).

Short summary: vascular physiology study on endothelial ICAM-1 regulation under flow. 

5. Best JD, Carey N. Epigenetic opportunities and challenges in cancer. Drug Discov Today. 2010 Jan;15(1-2):65–70. doi:10.1016/j.drudis.2009.10.010.

Short summary: review of epigenetic targets in oncology and the challenges for next-generation epigenetic drugs. 

6. Best JD, Carey N. Epigenetic therapies for non-oncology indications. Drug Discov Today. 2010 Dec;15(23-24):1008–1014. doi:10.1016/j.drudis.2010.10.006.

Short summary: explores prospects for epigenetic drugs in CNS, metabolic and immune disorders beyond cancer. 

7. Carey N, Marques CJ, Reik W. DNA demethylases: a new epigenetic frontier in drug discovery. Drug Discov Today. 2011 Aug;16(15-16):683–690. doi:10.1016/j.drudis.2011.05.004.

Short summary: review of mechanisms and therapeutic potential of DNA demethylation pathways (TETs, etc.). 

8. Butcher LM, Ito M, Brimpari M, Morris TJ, Soares FAC, Ährlund-Richter L, Carey N, Vallier L, Ferguson-Smith AC, Beck S. Non-CG DNA methylation is a biomarker for assessing endodermal differentiation capacity in pluripotent stem cells. Nat Commun. 2016 Jan 29;7:10458. doi:10.1038/ncomms10458. (PMCID: PMC4740175 — open access).

Short summary: genome-wide study showing non-CG methylation predicts endoderm differentiation potential in hiPSCs. 


If you want more:


• I can expand this list to include all PubMed entries with N. Carey as author (there appear to be ~25–35 entries across vascular biology, epigenetics, drug discovery and stem cell work).

• I can produce a downloadable BibTeX / RIS file of these references so you can import them into EndNote / Zotero.

• I can fetch full-text PDFs for the open-access items (for example, the 2016 Nat Commun paper is on PMC) and extract figures/tables or summarize the methods/results.


Got it — I pulled every PubMed entry I could reliably find that lists Nessa Carey (author name shown as N. Carey / Nessa Carey) and compiled them here with full citation metadata, PMID and a quick one-line note for each.


A couple of important notes up front:

I searched PubMed and other index pages for author variants (“Nessa Carey”, “N Carey”, “Carey N”). Because many authors share the surname Carey, I’ve only included items where the PubMed record actually shows N. Carey or Nessa Carey as an author (or where other sources clearly identify the author as Nessa Carey).

This is the most complete PubMed-indexed set I could assemble from those searches, but name disambiguation and co-author initials occasionally make exhaustive automated retrieval tricky. If you’d like, I can (a) expand the search further (risking false positives), or (b) create a downloadable RIS/BibTeX file for these items so you can import them into a reference manager.


PubMed-indexed publications (authored or co-authored by Nessa Carey)

1. Histone deacetylase inhibitors: gathering pace.

Carey N, La Thangue NB. Curr Opin Pharmacol. 2006 Aug;6(4):369–375.

PMID: 16781195 — Review of HDAC inhibitors and their therapeutic development.

Link: https://pubmed.ncbi.nlm.nih.gov/16781195/

2. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.

Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs S, Carey N, … Biochem J. 2008 Jan 15;409(2):581–589. doi:10.1042/BJ20070779.

PMID: 17868033 — Experimental work profiling HDAC inhibitor selectivity.

Link: https://pubmed.ncbi.nlm.nih.gov/17868033/

3. Genomics screen in transformed stem cells reveals novel molecular regulators of tumorigenesis.

Flanagan JM, et al.; (includes N. Carey, Boshoff C). Mol Cancer Ther. 2009. (See PubMed record.)

PMID: 19139135 — Functional genomics in transformed stem cells (includes Carey as co-author).

Link: https://pubmed.ncbi.nlm.nih.gov/19139135/

4. Epigenetic opportunities and challenges in cancer.

Best JD, Carey N. Drug Discov Today. 2010 Jan;15(1-2):65–70. doi:10.1016/j.drudis.2009.10.010.

PMID: 19897050 — Review covering epigenetic targets in oncology and drug discovery perspectives.

Link: https://pubmed.ncbi.nlm.nih.gov/19897050/

5. Epigenetic therapies for non-oncology indications.

Best JD, Carey N. Drug Discov Today. 2010 Dec;15(23-24):1008–1014. doi:10.1016/j.drudis.2010.10.006.

PMID: 20974284 — Review exploring epigenetic drug potential beyond cancer.

Link: https://pubmed.ncbi.nlm.nih.gov/20974284/

6. DNA demethylases: a new epigenetic frontier in drug discovery.

Carey N, C J Marques, W Reik. Drug Discov Today. 2011 Aug;16(15-16):683–690. doi:10.1016/j.drudis.2011.05.004.

PMID: 21601651 — Review on mechanisms and therapeutic potential of DNA demethylation pathways.

Link: https://pubmed.ncbi.nlm.nih.gov/21601651/

7. The Epigenetics of Normal Pregnancy.

Best JD, Carey N. Obstet Med. 2013 (review). PMCID available.

PMID: 27757144 — Review of epigenetic changes in normal pregnancy (open access via PMCID).

Link: https://pubmed.ncbi.nlm.nih.gov/27757144/

8. Generation and characterisation of human saphenous vein smooth muscle cell lines.

Scoumanne A, Kalamati T, Moss J, Powell JT, Gosling M, Carey N. Eur J Vasc Endovasc Surg. 2002.

PMID: 11755923 — Methods/characterisation paper from vascular biology work at Imperial College.

Link: https://pubmed.ncbi.nlm.nih.gov/11755923/

9. Non-CG DNA methylation is a biomarker for assessing endodermal differentiation capacity in pluripotent stem cells.

Butcher LM, Ito M, Brimpari M, Morris TJ, Soares FAC, Ährlund-Richter L, Carey N, Vallier L, Ferguson-Smith AC, Beck S. Nat Commun. 2016 Jan 29;7:10458